While AMGN shows strong recent momentum with a rally from $268 (April 2025) to $350.56 currently, the stock has already appreciated ~31% over the past year and is trading near 52-week highs, limiting near-term upside potential for a 2-12 week swing trade. The valuation metrics are stretched with a P/E of 25.2 and P/B of 23.84, and the concerning D/E ratio of 567.49 signals excessive leverage that could amplify downside risk if market sentiment shifts. Recent price action shows consolidation and pullback from the $390 level (Wells Fargo target), with the stock currently 10% below that target—suggesting limited catalyst for explosive 2-12 week gains and higher probability of sideways/downside movement. The low trading volumes in recent weeks (750K-7.5M shares vs. 9-18M earlier in the year) indicate weakening momentum, and with the stock already priced for optimism, the risk/reward for a swing trade entry at $350.56 is unfavorable; better entry points would emerge on a pullback to $320-330 support levels.

Amgen's price action shows a healthy retracement from its recent peak of $391.29 to the current $350.56 level, finding support near the $340 mark which previously acted as resistance. Fundamentally, the company remains robust with a high ROE of 96.2% and strong gross margins of 72.1%, though the high debt-to-equity ratio requires monitoring. Key risks over the next 12 weeks include potential volatility from clinical study updates and broader sector pressure, but the recent price target increase to $390 by Wells Fargo and significant institutional buying suggest strong underlying sentiment. This setup provides a favorable entry point for a swing trade, with an estimated upside potential of 10-12% as the stock attempts to reclaim its 52-week highs.

Price action shows a clear pullback from the recent high of $391.29 in early March 2026 to a low of $335.06 last week, with the current price at $350.56 representing a rebound and potential entry point at the start of upward momentum after the dip. Fundamentals are solid with exceptional ROE of 96.2%, high gross margins of 72.1%, net margins of 19.5%, and a attractive dividend yield of 3.08%, though the extremely high D/E ratio of 567.49 indicates heavy leverage; revenue growth is modest but steady. Key risks over the 2-12 week horizon include biotech pipeline uncertainties from the news of ending Anti-OX40 clinical studies, potential debt servicing pressures if interest rates rise, and low beta (0.46) limiting explosive upside in a volatile market. Final verdict is BUY, targeting 10-15% upside to $390+ based on Wells Fargo's raised price target and insider buying signals like Ken Fisher's doubled position, suitable for a swing trade profit on the rebound.